



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: AHARONI=5B

In re Application of:)	Conf. No.: 6949
)	
Rina AHARONI et al.)	Art Unit: 1646
)	
Appln. No.: 09/831,629)	Examiner:
)	
Filed: August 17, 2001)	Washington, D.C.
)	
For: PHARMACEUTICAL)	October 8, 2002
COMPOSITIONS COMPRISING)	
SYNTHETIC PEPTIDE ...)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

(Check one of the boxes A-D)

[] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[A] B. before the mailing date of a first office action on the merits.

RECEIVED
OCT 09 2002
TECH CENTER 1600/2900
P#6

☐ C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below).

(Check one of the boxes "i" and "ii" below:)

☐ i. Counsel certifies that, upon information and belief, each item of information listed herein was either

☐ (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this IDS.

(use one and delete other of following)

☐ ii. A check (check no. _____) for the fee set forth in §1.17(p), presently believed to be \$180, is enclosed. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035.

☐ ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(p), presently believed to be \$180. If the enclosed payment is incorrect,

please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035.

☐ D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant(s) petitions under 37 CFR \$1.97(d) for consideration of this IDS. **(use one and delete other of following and this note)** A check (check no. _____) for/ Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in \$1.17(i), presently believed to be \$130 is enclosed. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035. Counsel certifies that, upon information and belief, each item of information listed herein was either

☐ (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in \$1.56(c) more than three months prior to the filing of this IDS.

☒ 2. In accordance with 37 CFR \$1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an

attachment hereto. A copy of each document listed is attached, except as explained below.

☐ A. Document(s) _____ is (are) deemed substantially cumulative to document(s) _____, and, in accordance with §1.98(c), only a copy of each of the latter documents is enclosed.

☐ B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

(insert serial numbers and filing dates of prior applications)
Applicant(s) identifies these documents by attaching hereto copies of the forms PTO-892 and PTO-1449/SB-08A from the files of the prior application(s) or a fresh PTO-1449/SB-08A listing these documents, and request that they be considered and made of record in accordance with §1.98(d). Per 37 CFR §1.98(d), copies of these documents need not be filed in this application.

☐ 3. Document(s) _____ is (are) not in the English language. In accordance with §1.98(c), Applicant(s) states:

☐ An English translation of each document _____ (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.

☐ A concise explanation of the relevance of document(s) _____ is found in the attached _____ search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

☐ A concise explanation of the relevance of document(s) _____ is set forth as follows:

(insert concise explanation of relevance)

[] A concise explanation of the relevance of document(s) _____ can be found on page(s) _____ of the specification.

[] A concise explanation of document(s) _____ can be found on the attached sheet.

[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

[] 5. Other information being provided for the examiner's consideration follows:


(insert other information)

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:



Allen C. Yun
Reg. No. 37,971

ACY:rd
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/831,629
Filing Date	August 17, 2001
First Named Inventor	Rina AHARONI
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	AHARONI=5B

RECEIVED

OCT 09 2002

TECH CENTER 1000/2900

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/831,629
		Filing Date	August 17, 2001
		First Named Inventor	Rina AHARONI
		Group Art Unit	1646
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	AHARONI=5B

RECEIVED
OCT 09 2002
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AI	AHARONI et al, "Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease", <u>Immunol Lett</u> 58(2):79-87 (1997)	
	AJ	FRIDKIS-HARELI et al, "Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity", <u>Proc Natl Acad Sci USA</u> 91(11):4872-4876 (1994)	
	AK	FRIDKIS-HARELI et al, "Binding of random copolymers of three amino acids to class II MHC molecules", <u>Int Immunol</u> 11(5):635-641 (1999)	
	AL	LI et al, "Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma", <u>Eur J Pharmacol</u> 342(2-3):303-310 (1998)	
	AM	SCHLEGEL et al, "A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo", <u>Proc Natl Acad Sci USA</u> 93(10):5061-5066 (1996)	
	AN	SELA et al, "Suppressive activity of COP-1 in EAE and its relevance to multiple sclerosis", <u>Bull Inst Pasteur</u> 88:303-314 (1990)	
	AO	TEITELBAUM et al, "Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide", <u>Eur J Immunol</u> 1(4):242-248 (1971)	
	AP	TEITELBAUM et al, "Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1", <u>Proc Natl Acad Sci USA</u> 88(21):9528-19532 (1991)	
	AQ	TEITELBAUM et al, "Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein", <u>Proc Natl Acad Sci USA</u> 89(1):137-141 (1992)	
	AR	TEITELBAUM et al, "Copolymer 1 from the laboratory to FDA", <u>Isr J Med Sci</u> 33(4):280-284 (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.